XIII INTERNATIONAL CHARLES HEIDELBERGER SYMPOSIUM and 50 YEARS OF FLUOROPYRIMIDINES IN CANCER THERAPY (New York University Cancer Institute, Smilow Conference Center)

Wednesday, September 5, 2007: 6-8PM Welcoming Reception

Thursday, September 6, 2007: 8AM Registration

8:30 Welcome and Introduction to the 13th Heidelberger Symposium (Steven Burakoff, Franco Muggia, Howard Hochster)

Session I: Environmental Carcinogenesis, Cancer epidemiology & Cancer Detection (Curtis Harris, Chair)
8:45 AM-Noon Environmental carcinogenesis (Eric Tang)
   Mutagenic activity of carcinogens (Joe Guttenplan)
   Carcinogen-DNA adducts (Nicholas Geacintov)
   Radiation and other DNA damaging agents (Al Fornace)
   Inflammation and cancer: interaction of the p53, cytokine and microRNA pathways (Curtis Harris)
   Molecular strategies for lung cancer detection (Bill Rom)
   Skin Carcinogenesis (Fredika Mikles Robertson)

Noon-1:30 Lunch

Session II: Cancer Biology (Eli Huberman, Chair)
1:30-5PM Hormone-related tumors in women (Malcolm Pike)
   Interaction between environmental and genetic risk factors for ovarian carcinoma (Louis Dubeau)
   Stem Cells (Eliezer Huberman)
   Mitotic Regulation (Wei Dai)
   Retinoids: roles inhibiting carcinogenesis (John Bertram)
   Translation and Angiogenesis in breast cancer (Robert Schneider)
   Leukemia: oncogenic mechanisms (Ari Melnick)

6-8:00 PM Wine & Cheese with Poster Displays
Friday September 7, 2007

**Session III: Models of Cancer Causation & Treatment Interventions**  
(*Joseph Landolph & Max Costa, Chairs*)

8:30-Noon  
New Opportunities for Thymidylate Metabolism as a Therapeutic Target (*Joseph Landolph*)  
Epigenetic Mechanisms of Nickel carcinogenesis (*Max Costa*)  
DNA methylation (*Shirley Taylor*)  
Tyrosine kinase inhibitors (*Rob Kramer*)  
Skin carcinogenesis (*Stuart Yuspa*)  
Ovarian cancer (*Daniela Dinulescu*)

Noon-1:30  
Lunch; Poster Displays

**Session IV: Therapeutic Targets and Novel Strategies in Gastrointestinal (GI) Cancer**  
(*Richard Moran & Joseph Bertino, Chairs*)

1:30-5:30PM  
1:30-1:55 Overview of 5-FU pharmacodynamics (*Giuseppe Pizzorno*)  
1:55-2:20 Reversal of 5-FU resistance by epigenetic modulation (*Joe Bertino*)  
2:20-2:45 Drugs targeting Topoisomerases (*Yves Pommier*)  
2:45-3:10 ISG15: a potential biomarker for sensitivity to topoisomerase I-targeting drugs (*Leroy Liu*)  
3:10-3:35 FUDR: unique features in locoregional therapy (*Nancy Kemeny, Franco Muggia*)  
3:35-3:55 The changing role of surgery (Gastric Cancer)  
(*Elliot Newman*)  
3:55-4:15 The changing role of surgery (Colorectal Cancer)  
(*Karl-Heinrich Link*)  
4:15-4:40 Molecular staging of colorectal cancer (*Stan Hamilton*)  
4:40-5:05 Colorectal cancer treatment: from 1957 to the present (*Edward Chu*)
5:05-5:30  Treatment of other GI cancers (*Howard Hochster*)

5:30-6:30PM Poster Discussion: drug development and phase I/II trials (*Giuseppe Pizzorno, Howard Hochster*)

7:00 PM  Faculty Dinner
Remembering Charlie Heidelberger (*Joe Landolph, Richard Moran, Eli Huberman, Peter Danenberg, others*)
Saturday September 8, 2007

**Session V: Therapeutic Targets and Novel Strategies in GI & Breast Cancers**  
*Masatoshi Watanabe & Franco Muggia, Chairs*

8:30-1:30PM

8:30-8:55  Microenvironment and drug resistance (*Masatoshi Watanabe*)

8:55-9:20  IGF-1 signaling as a potential target (*Peter Houghton*)

9:20-9:45  Gene expression profiling of tumors using RNA from formalin-fixed paraffin-embedded tissue samples (*Peter Danenberg*)

9:45-10:10  Thymidylate synthase gene polymorphisms (*Robert Ladner*)

10:10-10:30 Break

10:30-10:55 Clinical predictive markers of drug action and implications for drug development (*Heinz Lenz*)

10:55-11:20 The new-generation antifolate - pemetrexed (*I David Goldman*)

11:20-11:45 Novel antimetabolites (*Ann Jackman*)

11:45-12:10 Control of FPGS expression (*Richard Moran*)

12:10-12:35 Gemcitabine: tracking its activation (*William Plunkett*)

12:35-1:00 Gemcitabine pharmacodynamics and pharmacogenomics (*Godfriedus Peters*)

1:00-1:25  Gene expression profiles directing cancer therapy (*Joffre Baker*)

1:25-1:30  Concluding remarks (*Franco Muggia, Joe Landolph*)